相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction
Jan C. Brase et al.
CLINICAL CANCER RESEARCH (2010)
Evaluation of Treatment-Effect Heterogeneity Using Biomarkers Measured on a Continuous Scale: Subpopulation Treatment Effect Pattern Plot
Ann A. Lazar et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy
F. P. O'Malley et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2009)
Type 1 Receptor Tyrosine Kinase Profiles Identify Patients With Enhanced Benefit From Anthracyclines in the BR9601 Adjuvant Breast Cancer Chemotherapy Trial
John M. S. Bartlett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2/neu in systemic therapy for women with breast cancer:: a systematic review
Bindi Dhesy-Thind et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer
Christopher J. Poole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Topoisomerase IIα gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer:: Scandinavian Breast Group Trial 9401
Minna Tanner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
HER2 and responsiveness of breast cancer to adjuvant chemotherapy
KI Pritchard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil:: Danish Breast Cancer Cooperative Group
AS Knoop et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy:: influenced by the HER2- and Topoisomerase IIα-status of the primary tumor?
C Schindlbeck et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2005)
Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5
MN Levine et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIα for anthracycline chemotherapy in locally advanced breast cancer
G Arpino et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
Topoisomerase IIα and APE/ref-1 are associated with pathologic response to primary anthracycline-based chemotherapy for breast cancer
AM Minisini et al.
CANCER LETTERS (2005)
c-erbB2 and topoisomerase II alpha protein expression independently predict poor survival in primary human breast cancer: a retrospective study
P Fritz et al.
BREAST CANCER RESEARCH (2005)
Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples
RE Mueller et al.
GENES CHROMOSOMES & CANCER (2004)
Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy
M Martin-Richard et al.
ONCOLOGY (2004)
DNA topoisomerase IIα expression and the response to primary chemotherapy in breast cancer
G MacGrogan et al.
BRITISH JOURNAL OF CANCER (2003)
Role of proliferation in HER2 status predicted response to doxorubicin
M Campiglio et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
HER-2 and topo-isomerase IIα as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
A Di Leo et al.
ANNALS OF ONCOLOGY (2001)
分享论文
